Syndeio Biosciences

Syndeio Biosciences is a private, clinical-stage biotech developing synapse-targeted therapeutics for disorders like major depressive disorder (MDD) and Alzheimer's disease. Its core innovation is the Boost Platform™, a proprietary synapse pharmacology model originating from Nobel laureate Thomas Südhof's lab, which it uses to discover and characterize novel positive allosteric modulators (PAMs) of the NMDA receptor. The company's lead assets, zelquistinel (oral) and apimostinel (injectable), are in Phase 2 trials, with a focus on establishing rapid-acting, durable efficacy with improved safety profiles compared to existing NMDAR-targeted therapies. Syndeio is strategically leveraging precision neuroscience tools and biomarkers to de-risk clinical development in large, underserved patient populations.

Boost Platform™: A proprietary integrated synapse pharmacology model originating from the Südhof lab at Stanford. It combines molecular, functional, and behavioral models to discover and characterize novel drugs, particularly focused on event-driven pharmacology via positive allosteric modulators (PAMs) of the NMDA receptor to enhance synaptic strength and function.

Syndeio competes in the rapidly evolving space of rapid-acting antidepressants and synaptic modulators. Direct competitors include companies developing ketamine/esketamine alternatives, other NMDAR modulators (e.g., Gate Neurosciences, Perception Neuroscience), and psychedelic-derived therapies (e.g., Compass Pathways). In Alzheimer's, it faces competition from large pharma and biotech companies pursuing amyloid, tau, and other mechanisms. Syndeio's differentiation hinges on its unique NMDAR PAM pharmacology, oral/injectable formulations, and focus on safety and tolerability.